CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundationa...
December 16 2016 - 7:00AM
CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics
(NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that
the companies and their licensors have entered into a global
cross-consent and invention management agreement for the
foundational intellectual property covering CRISPR/Cas9 gene
editing technology. The parties to the agreement include the
co-owners of the intellectual property – the Regents of the
University of California, Emmanuelle Charpentier, and the
University of Vienna – as well as key licensees and sublicensees –
CRISPR Therapeutics, ERS Genomics, Caribou Biosciences, and
Intellia Therapeutics.
Under the agreement, the parties commit to maintain and
coordinate the prosecution, defense and enforcement of the
CRISPR/Cas9 foundational patent portfolio worldwide, and each of
the co-owners of the intellectual property grants cross-consents to
all existing and future licenses and sublicenses based on the
rights of another co-owner. “We are pleased that we have come to
this global agreement with Intellia, Caribou, ERS and the co-owners
and other licensees of this foundational CRISPR/Cas9 technology
IP,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “We
believe that the Charpentier-University of California-Vienna IP
estate constitutes the foundational IP in the CRISPR/Cas9 editing
space. Intellia, CRISPR Therapeutics, Caribou, and ERS view
this agreement as enhancing the efforts to protect our shared
intellectual property rights and support the ongoing development of
our product candidates, as well as those of our corresponding
partners and licensees.”
“Through this agreement, we are ensuring alignment in our
efforts to protect and prosecute the foundational CRISPR/Cas9
discoveries made by Dr. Doudna, Dr. Charpentier, and their teams,
which have transformed the genomics field and unleashed new
therapeutic possibilities,” said Nessan Bermingham, CEO and
founder, Intellia Therapeutics. “This strengthens Intellia's IP
position as we continue forging ahead with the discovery and
development of therapies for patients worldwide.”
Rachel Haurwitz, President and CEO of Caribou Biosciences,
added, “We appreciate the efforts of the co-owners and licensees to
finalize this agreement and are pleased to move forward as each of
our companies develops products using this breakthrough CRISPR/Cas9
foundational IP.”
“This broadly enabling technology will be transformative across
such a wide range of areas,” said Eric Rhodes, CEO of ERS Genomics,
“and we are thrilled to now be able to offer worldwide access to
this important technology.”
About CRISPR TherapeuticsCRISPR Therapeutics is
a leading gene-editing company focused on developing transformative
gene-based medicines for serious diseases using its proprietary
CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary
technology that allows for precise, directed changes to genomic
DNA. The Company's multi-disciplinary team of world-class
researchers and drug developers is working to translate this
technology into breakthrough human therapeutics in a number of
serious diseases. Additionally, CRISPR Therapeutics has established
strategic collaborations with Bayer AG and Vertex Pharmaceuticals
to develop CRISPR-based therapeutics in diseases with high unmet
need. The foundational CRISPR/Cas9 patent estate for human
therapeutic use was licensed from the Company's scientific founder
Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered
in Basel, Switzerland with its R&D operations based in
Cambridge, Massachusetts. For more information, please visit
www.crisprtx.com.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on the
development of proprietary, potentially curative therapeutics using
the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. Intellia’s combination of deep scientific,
technical and clinical development experience, along with its
leading intellectual property portfolio, puts it in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
About Caribou Biosciences, Inc.Caribou is a
developer of cellular engineering and analysis solutions based on
CRISPR technologies. The Company was founded by pioneers of
CRISPR/Cas9 biology based on research carried out in the Doudna
Laboratory at the University of California, Berkeley. Caribou's
tools and technologies provide transformative capabilities to
therapeutic development, agricultural biotechnology, industrial
biotechnology, and basic and applied biological research. For more
information, visit www.cariboubio.com and follow the Company
@CaribouBio. "Caribou Biosciences" and the Caribou logo are
trademarks of Caribou Biosciences, Inc.
About ERS Genomics ERS Genomics
was formed to provide broad access to the foundational CRISPR-Cas9
intellectual property held by Dr. Emmanuelle Charpentier.
Non-exclusive licenses are available for research and sale of
products and services across multiple fields including: research
tools, kits, reagents; discovery of novel targets for therapeutic
intervention; cell lines for discovery and screening of novel drug
candidates; GMP production of healthcare products; production of
industrial materials such as enzymes, biofuels and chemicals; and
synthetic biology. For additional information please visit
www.ersgenomics.com.
CRISPR Forward-Looking StatementCertain
statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning: the therapeutic value,
development, and commercial potential of CRISPR/Cas-9 gene editing
technologies and therapies and the intellectual property protection
of our technology and therapies. You are cautioned that
forward-looking statements are inherently uncertain. Although the
company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and they are necessarily subject to a high degree of
uncertainty and risk. Actual performance and results may differ
materially from those projected or suggested in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others: uncertainties regarding the
intellectual property protection for our technology and
intellectual property belonging to third parties; uncertainties
inherent in the initiation and completion of preclinical studies
for the Company’s product candidates; availability and timing of
results from preclinical studies; whether results from a
preclinical trial will be predictive of future results of the
future trials; expectations for regulatory approvals to conduct
trials or to market products; and those risks and uncertainties
described in Item 1A under the heading “Risk Factors” in the
company’s most recent quarterly report on Form 10-Q, and in any
other subsequent filings made by the company with the U.S.
Securities and Exchange Commission (SEC), which are available
on the SEC’s website at www.sec.gov. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. The information contained in this press release is
provided by the company as of the date hereof, and, except as
required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
information contained in this press release.
Intellia’s Forward-Looking StatementThis press
release contains “forward-looking statements” of Intellia within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward looking statements include, but are not limited
to, statements regarding Intellia’s ability to advance CRISPR/Cas9
into therapeutic products for severe and life-threatening diseases
and its CRISPR/Cas9 intellectual property portfolio. Any
forward-looking statements in this press release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that any
one or more of Intellia’s product candidates will not be
successfully developed and commercialized, the risk of cessation or
delay of any of the ongoing or planned clinical trials and/or
development of Intellia’s product candidates, the risk that the
results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk that
Intellia’s collaborations with Novartis or Regeneron will
not continue or will not be successful, and risks related to
Intellia’s ability to protect and maintain its intellectual
property position. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled "Risk
Factors" in Intellia’s most recent quarterly report on Form 10-Q
filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in Intellia’s subsequent filings with the Securities
and Exchange Commission. All information in this press release
is as of the date of the release, and Intellia Therapeutics
undertakes no duty to update this information unless required by
law.
CRISPR Contacts:
Media: |
|
|
Investors: |
Jennifer Paganelli |
|
|
Chris Brinzey |
W2O Group for
CRISPR |
|
|
Westwicke Partners for
CRISPR |
347-658-8290 |
|
|
339-970-2843 |
jpaganelli@w2ogroup.com |
|
|
chris.brinzey@westwicke.com |
|
|
|
|
Intellia
Contacts: |
|
|
|
|
|
|
|
Media: |
|
|
Investors: |
Jennifer Mound
Smoter |
|
|
John Graziano |
Chief External Affairs
& Communications Officer |
|
|
Trout Group |
+1 857-706-1071 |
|
|
+ 1 646-378-2942 |
jenn.smoter@intelliatx.com |
|
|
jgraziano@troutgroup.com |
|
|
|
|
|
|
|
Chad Rubin |
|
|
|
Trout Group |
|
|
|
+ 1 646-378-2947 |
|
|
|
crubin@troutgroup.com |
|
|
|
|
Caribou Contacts:
Greg KelleyFeinstein Kean Healthcare404-836-2302
gregory.kelley@fkhealth.com
ERS Genomics Contacts:
MacDougall Biomedical CommunicationsMario Brkulj or Dr.
Stephanie MayDirect: +49 89 2420 9345 or +48 89 2420
9344E-Mail: mbrkulj@macbiocom.com or smay@macbiocom.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024